Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 7.88% and Operating profit at -24.68% over the last 5 years
2
The company has declared positive results in Mar'2025 after 9 consecutive negative quarters
3
With ROE of 1.92%, it has a expensive valuation with a 2.83 Price to Book Value
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,820 Million (Mid Cap)
147.00
NA
0.01%
-0.32
1.92%
2.83
Revenue and Profits:
Net Sales:
132 Million
(Quarterly Results - Jun 2025)
Net Profit:
21 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-29.07%
0%
-29.07%
6 Months
6.97%
0%
6.97%
1 Year
0.26%
0%
0.26%
2 Years
4.77%
0%
4.77%
3 Years
-14.76%
0%
-14.76%
4 Years
-11.56%
0%
-11.56%
5 Years
-36.34%
0%
-36.34%
Shanghai Sanyou Medical Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.88%
EBIT Growth (5y)
-24.68%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.25
Tax Ratio
26.42%
Dividend Payout Ratio
7.58%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.81%
ROE (avg)
6.42%
Valuation key factors
Factor
Value
P/E Ratio
147
Industry P/E
Price to Book Value
2.83
EV to EBIT
216.60
EV to EBITDA
61.57
EV to Capital Employed
3.68
EV to Sales
10.66
PEG Ratio
4.41
Dividend Yield
0.01%
ROCE (Latest)
1.70%
ROE (Latest)
1.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
131.50
115.20
14.15%
Operating Profit (PBDIT) excl Other Income
27.90
27.70
0.72%
Interest
0.80
0.00
Exceptional Items
-0.20
-0.00
Consolidate Net Profit
21.30
10.60
100.94%
Operating Profit Margin (Excl OI)
97.60%
109.90%
-1.23%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 14.15% vs -3.60% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 100.94% vs 171.79% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
447.90
454.40
-1.43%
Operating Profit (PBDIT) excl Other Income
67.30
155.90
-56.83%
Interest
2.50
0.50
400.00%
Exceptional Items
-6.00
15.80
-137.97%
Consolidate Net Profit
12.10
113.60
-89.35%
Operating Profit Margin (Excl OI)
13.20%
223.40%
-21.02%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -1.43% vs -29.17% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -89.35% vs -44.20% in Dec 2023
About Shanghai Sanyou Medical Co. Ltd. 
Shanghai Sanyou Medical Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






